LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation

NCT07391566 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

99

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Colorectal Cancer (mCRC)

Interventions

DRUG: LPM6690176
BIOLOGICAL: Bevacizumab
DRUG: FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)

Sponsor

Luye Pharma Group Ltd.